抗动脉样硬化策略的最新进展和潜在的治疗目标
Zhongmin Wang1, Xiao He1, Huayang Bai1
1Chongqing Key Laboratory of Medicinal Chemistry and Molecular Pharmacology, Chongqing University of Technology, Chongqing 400054, China.
International journal of pharmaceutics
|August 31, 2025
概括
本综述探讨了先进的动脉样硬化治疗方法,包括小分子,PCSK9抑制剂等大分子和纳米药物. 它强调了应对这一具有挑战性的心血管疾病的创新策略.
科学领域:
- 心血管医学
- 药理学
- 纳米技术
背景情况:
- 动脉样硬化涉及脂质积累和斑块形成,导致动脉狭窄.
- 目前的治疗方法可以控制病情的进展,但不能治愈,这带来持续的挑战.
- 生物医学的进步需要新的动脉样硬化治疗方法.
研究的目的:
- 系统地审查动脉样硬化治疗的最新进展.
- 涵盖小分子药物,宏分子疗法和纳米医学.
- 讨论动脉样硬化创新疗法的潜力和挑战.
主要方法:
- 小分子药物 (蛋白向抑制剂/激动剂,天然化合物) 的文献综述.
- 对宏分子药物的审查,重点是蛋白转化酶9型 (PCSK9) 抑制剂.
- 纳米医学应用和协同治疗效果的分析.
主要成果:
- 小分子利用蛋白质标调节和自然化合物.
- 大分子策略包括先进的PCSK9抑制剂.
- 纳米医学提供协同效应和创新的治疗设计.
结论:
- 在治疗动脉样硬化方面,
- 在将新疗法转化为临床实践方面仍然存在挑战.
- 创新的设计概念对于未来的动脉样硬化治疗发展至关重要.
更多相关视频
相关概念视频
Atherosclerosis III: Management
33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33
Atherosclerosis IV: Nursing Management
50
Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
50
Atherosclerosis I: Introduction
76
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
76
Peripheral Artery Disease III: Interprofessional Care
29
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
29
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
38
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
38
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505


